You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

Details for New Drug Application (NDA): 204734


✉ Email this page to a colleague

« Back to Dashboard


NDA 204734 describes FOSRENOL, which is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from two suppliers. There are four patents protecting this drug and two Paragraph IV challenges. Additional details are available on the FOSRENOL profile page.

The generic ingredient in FOSRENOL is lanthanum carbonate. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the lanthanum carbonate profile page.
Summary for 204734
Tradename:FOSRENOL
Applicant:Takeda Pharms Usa
Ingredient:lanthanum carbonate
Patents:3
Pharmacology for NDA: 204734
Mechanism of ActionPhosphate Chelating Activity
Suppliers and Packaging for NDA: 204734
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FOSRENOL lanthanum carbonate POWDER;ORAL 204734 NDA Takeda Pharmaceuticals America, Inc. 54092-256 54092-256-02 9 CARTON in 1 PACKAGE (54092-256-02) / 10 POWDER in 1 CARTON (54092-256-01)
FOSRENOL lanthanum carbonate POWDER;ORAL 204734 NDA Takeda Pharmaceuticals America, Inc. 54092-257 54092-257-02 9 CARTON in 1 CARTON (54092-257-02) / 10 POWDER in 1 CARTON (54092-257-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;ORALStrengthEQ 750MG BASE
Approval Date:Sep 24, 2014TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Aug 26, 2024Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Sign UpPatent Expiration:Dec 1, 2030Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Sign UpPatent Expiration:Dec 1, 2030Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 204734

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa FOSRENOL lanthanum carbonate POWDER;ORAL 204734-001 Sep 24, 2014 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa FOSRENOL lanthanum carbonate POWDER;ORAL 204734-002 Sep 24, 2014 ⤷  Sign Up ⤷  Sign Up
Takeda Pharms Usa FOSRENOL lanthanum carbonate POWDER;ORAL 204734-001 Sep 24, 2014 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.